143 related articles for article (PubMed ID: 31492673)
1. Transdermal fentanyl to parenteral morphine route switch and drug rotation in refractory cancer cachexia.
Alsirafy SA; Alabdullateef SH; Elyamany AM; Hassan AD; Almashiakhi M
BMJ Support Palliat Care; 2022 Jul; 12(e2):e184-e186. PubMed ID: 31492673
[TBL] [Abstract][Full Text] [Related]
2. Opioid rotation from transdermal fentanyl to continuous subcutaneous hydromorphone in a cachectic patient: A case report and review of the literature.
Jackson LD; Wortzman R; Chua D; Selby D
J Oncol Pharm Pract; 2021 Jan; 27(1):238-243. PubMed ID: 32501183
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
4. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.
Ripamonti C; Fagnoni E; Campa T; Brunelli C; De Conno F
Support Care Cancer; 2006 May; 14(5):400-7. PubMed ID: 16485087
[TBL] [Abstract][Full Text] [Related]
5. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
6. Fentanyl use disorder characterized by unprescribed use of transdermal patches: a case report.
Guliyev C; Tuna ZO; Ögel K
J Addict Dis; 2022; 40(2):285-290. PubMed ID: 34445944
[TBL] [Abstract][Full Text] [Related]
7. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.
Donner B; Zenz M; Tryba M; Strumpf M
Pain; 1996 Mar; 64(3):527-534. PubMed ID: 8783318
[TBL] [Abstract][Full Text] [Related]
8. Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch.
Chiba T; Takahashi H; Tairabune T; Kimura S; Ueda H; Kudo K
Biol Pharm Bull; 2020; 43(5):873-878. PubMed ID: 32378563
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain.
Miyazaki T; Hanaoka K; Namiki A; Ogawa S; Kitajima T; Hosokawa T; Ishida T; Nogami S; Mashimo S
Clin Drug Investig; 2008; 28(5):313-25. PubMed ID: 18407717
[TBL] [Abstract][Full Text] [Related]
10. Unusual case of transdermal fentanyl in cachexia.
Lam D; Kay S; Pickard J; Harrison S
BMJ Support Palliat Care; 2019 Dec; 9(4):363-364. PubMed ID: 30612090
[TBL] [Abstract][Full Text] [Related]
11. Transdermal fentanyl in cachectic cancer patients.
Heiskanen T; Mätzke S; Haakana S; Gergov M; Vuori E; Kalso E
Pain; 2009 Jul; 144(1-2):218-22. PubMed ID: 19442446
[TBL] [Abstract][Full Text] [Related]
12. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
13. Therapy switching in patients receiving long-acting opioids.
Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
[TBL] [Abstract][Full Text] [Related]
14. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
Allan L; Hays H; Jensen NH; de Waroux BL; Bolt M; Donald R; Kalso E
BMJ; 2001 May; 322(7295):1154-8. PubMed ID: 11348910
[TBL] [Abstract][Full Text] [Related]
15. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
16. [Optimal conversion ratio of oral morphine to transdermal fentanyl patches to the cancer pain].
Ogawa J; Nakamura K; Iizuka K; Sekizuka M; Yamamoto K; Horiuchi R
Yakugaku Zasshi; 2009 Mar; 129(3):335-40. PubMed ID: 19252390
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
Payne R
Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
[TBL] [Abstract][Full Text] [Related]
18. Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer.
Takakuwa O; Oguri T; Maeno K; Yokoyama M; Hijikata H; Uemura T; Ozasa H; Ohkubo H; Miyazaki M; Niimi A
Am J Hosp Palliat Care; 2013 Nov; 30(7):726-9. PubMed ID: 23264661
[TBL] [Abstract][Full Text] [Related]
19. Postoperative analgesia with parenteral opioids: does continuous delivery utilizing a transdermal opioid preparation affect analgesic efficacy or patient safety?
Sevarino FB; Paige D; Sinatra RS; Silverman DG
J Clin Anesth; 1997 May; 9(3):173-8. PubMed ID: 9172021
[TBL] [Abstract][Full Text] [Related]
20. Postoperative analgesia after total hip arthroplasty: patient-controlled analgesia versus transdermal fentanyl patch.
Minville V; Lubrano V; Bounes V; Pianezza A; Rabinowitz A; Gris C; Samii K; Fourcade O
J Clin Anesth; 2008 Jun; 20(4):280-3. PubMed ID: 18617126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]